LSD1+8a 是神经内分泌性前列腺癌的 RNA 生物标记物

IF 4.8 2区医学 Q1 Biochemistry, Genetics and Molecular Biology

Neoplasia Pub Date : 2025-03-14 DOI:10.1016/j.neo.2025.101151

Anbarasu Kumaraswamy , Rahul Mannan , Olivia A. Swaim , Eva Rodansky , Xiao-Ming Wang , Aaron Udager , Rohit Mehra , Hui Li , Colm Morrissey , Eva Corey , Michael C. Haffner , Peter S. Nelson , Arul M. Chinnaiyan , Joel A. Yates , Joshi J. Alumkal

{"title":"LSD1+8a 是神经内分泌性前列腺癌的 RNA 生物标记物","authors":"Anbarasu Kumaraswamy , Rahul Mannan , Olivia A. Swaim , Eva Rodansky , Xiao-Ming Wang , Aaron Udager , Rohit Mehra , Hui Li , Colm Morrissey , Eva Corey , Michael C. Haffner , Peter S. Nelson , Arul M. Chinnaiyan , Joel A. Yates , Joshi J. Alumkal","doi":"10.1016/j.neo.2025.101151","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Lysine-specific demethylase 1 (LSD1) is a histone demethylase and regulator of differentiation, including in cancer. A neuronal-specific isoform of <em>LSD1</em>—<em>LSD1+8a</em>—has been shown to play a key role in promoting neuronal differentiation in the developing brain. We previously determined that <em>LSD1+8a</em> transcripts were detected in an aggressive subtype of prostate cancer harboring a neuronal program—neuroendocrine prostate cancer (NEPC)—but not in prostate adenocarcinomas harboring a glandular program. However, the number of samples examined was limited.</div></div><div><h3>Methods</h3><div>Using a large collection of prostate cancer patient cell lines and patient-derived xenografts (PDXs), we measured LSD1+8a using quantitative polymerase chain reaction (qPCR), RNA <em>in situ</em> hybridization (RNA-ISH), and protein detection methods. We then validated our findings using an independent cohort of patient tumor samples.</div></div><div><h3>Results</h3><div><em>LSD1+8a</em> mRNA expression was detected in every NEPC cell line and PDX examined by qPCR and RNA-ISH but in none of the prostate adenocarcinomas. We validated the RNA-ISH results in patient tumors, confirming that <em>LSD1+8a</em> was expressed in all NEPC tumors but in none of the adenocarcinomas. Finally, we generated a rabbit monoclonal antibody specific to LSD1+8a protein and confirmed its specificity using normal neuronal tissue samples. However, LSD1+8a protein was not detectable in NEPC tumors—likely due to the substantially lower levels of <em>LSD1+8a</em> mRNA in NEPC tumors vs. normal neuronal tissues.</div></div><div><h3>Conclusions</h3><div>Measuring <em>LSD1+</em>8a mRNA is a sensitive and specific method for the diagnosis of NEPC, which is often challenging.</div></div>","PeriodicalId":18917,"journal":{"name":"Neoplasia","volume":"63 ","pages":"Article 101151"},"PeriodicalIF":4.8000,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"LSD1+8a is an RNA biomarker of neuroendocrine prostate cancer\",\"authors\":\"Anbarasu Kumaraswamy , Rahul Mannan , Olivia A. Swaim , Eva Rodansky , Xiao-Ming Wang , Aaron Udager , Rohit Mehra , Hui Li , Colm Morrissey , Eva Corey , Michael C. Haffner , Peter S. Nelson , Arul M. Chinnaiyan , Joel A. Yates , Joshi J. Alumkal\",\"doi\":\"10.1016/j.neo.2025.101151\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Lysine-specific demethylase 1 (LSD1) is a histone demethylase and regulator of differentiation, including in cancer. A neuronal-specific isoform of <em>LSD1</em>—<em>LSD1+8a</em>—has been shown to play a key role in promoting neuronal differentiation in the developing brain. We previously determined that <em>LSD1+8a</em> transcripts were detected in an aggressive subtype of prostate cancer harboring a neuronal program—neuroendocrine prostate cancer (NEPC)—but not in prostate adenocarcinomas harboring a glandular program. However, the number of samples examined was limited.</div></div><div><h3>Methods</h3><div>Using a large collection of prostate cancer patient cell lines and patient-derived xenografts (PDXs), we measured LSD1+8a using quantitative polymerase chain reaction (qPCR), RNA <em>in situ</em> hybridization (RNA-ISH), and protein detection methods. We then validated our findings using an independent cohort of patient tumor samples.</div></div><div><h3>Results</h3><div><em>LSD1+8a</em> mRNA expression was detected in every NEPC cell line and PDX examined by qPCR and RNA-ISH but in none of the prostate adenocarcinomas. We validated the RNA-ISH results in patient tumors, confirming that <em>LSD1+8a</em> was expressed in all NEPC tumors but in none of the adenocarcinomas. Finally, we generated a rabbit monoclonal antibody specific to LSD1+8a protein and confirmed its specificity using normal neuronal tissue samples. However, LSD1+8a protein was not detectable in NEPC tumors—likely due to the substantially lower levels of <em>LSD1+8a</em> mRNA in NEPC tumors vs. normal neuronal tissues.</div></div><div><h3>Conclusions</h3><div>Measuring <em>LSD1+</em>8a mRNA is a sensitive and specific method for the diagnosis of NEPC, which is often challenging.</div></div>\",\"PeriodicalId\":18917,\"journal\":{\"name\":\"Neoplasia\",\"volume\":\"63 \",\"pages\":\"Article 101151\"},\"PeriodicalIF\":4.8000,\"publicationDate\":\"2025-03-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neoplasia\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1476558625000302\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Biochemistry, Genetics and Molecular Biology\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neoplasia","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1476558625000302","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}

引用次数: 0

摘要

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

LSD1+8a is an RNA biomarker of neuroendocrine prostate cancer

Background

Lysine-specific demethylase 1 (LSD1) is a histone demethylase and regulator of differentiation, including in cancer. A neuronal-specific isoform of LSD1—LSD1+8a—has been shown to play a key role in promoting neuronal differentiation in the developing brain. We previously determined that LSD1+8a transcripts were detected in an aggressive subtype of prostate cancer harboring a neuronal program—neuroendocrine prostate cancer (NEPC)—but not in prostate adenocarcinomas harboring a glandular program. However, the number of samples examined was limited.

Methods

Using a large collection of prostate cancer patient cell lines and patient-derived xenografts (PDXs), we measured LSD1+8a using quantitative polymerase chain reaction (qPCR), RNA in situ hybridization (RNA-ISH), and protein detection methods. We then validated our findings using an independent cohort of patient tumor samples.

Results

LSD1+8a mRNA expression was detected in every NEPC cell line and PDX examined by qPCR and RNA-ISH but in none of the prostate adenocarcinomas. We validated the RNA-ISH results in patient tumors, confirming that LSD1+8a was expressed in all NEPC tumors but in none of the adenocarcinomas. Finally, we generated a rabbit monoclonal antibody specific to LSD1+8a protein and confirmed its specificity using normal neuronal tissue samples. However, LSD1+8a protein was not detectable in NEPC tumors—likely due to the substantially lower levels of LSD1+8a mRNA in NEPC tumors vs. normal neuronal tissues.

Conclusions

Measuring LSD1+8a mRNA is a sensitive and specific method for the diagnosis of NEPC, which is often challenging.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Neoplasia 医学-肿瘤学

CiteScore

9.20

自引率

2.10%

发文量

审稿时长

26 days

期刊介绍： Neoplasia publishes the results of novel investigations in all areas of oncology research. The title Neoplasia was chosen to convey the journal’s breadth, which encompasses the traditional disciplines of cancer research as well as emerging fields and interdisciplinary investigations. Neoplasia is interested in studies describing new molecular and genetic findings relating to the neoplastic phenotype and in laboratory and clinical studies demonstrating creative applications of advances in the basic sciences to risk assessment, prognostic indications, detection, diagnosis, and treatment. In addition to regular Research Reports, Neoplasia also publishes Reviews and Meeting Reports. Neoplasia is committed to ensuring a thorough, fair, and rapid review and publication schedule to further its mission of serving both the scientific and clinical communities by disseminating important data and ideas in cancer research.